CHICAGO -- Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients ...

Danny Rischin, MD, medical oncologist, clinician researcher, Peter McCallum Cancer Centre, discusses a novel adjuvant ...

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and ...

Postoperative nivolumab added to standard-of-care adjuvant cisplatin radiotherapy “represents a potential new standard.” ...